🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsOther Peptides & Research CompoundsAre any of these other peptides actually backed by science — May 2025

Are any of these other peptides actually backed by science — May 2025

maria_elpaso Wed, Apr 16, 2025 at 2:33 AM 16 replies 1,686 viewsPage 1 of 4
This thread is more than 13 months old. Information may be outdated. Consider searching for more recent discussions.
maria_elpaso
Member
312
1,456
Sep 2024
El Paso, TX
Apr 16, 2025 at 2:33 AM#1

Read the primary source rather than the write-up and the two do not agree, so here is what is actually in it.

The mechanism is more central than most summaries suggest. Receptor agonism in the arcuate nucleus activates POMC neurons and inhibits AgRP/NPY signalling, and the downstream MC4R pathway is the same one disrupted in monogenic obesity — convergent genetic evidence that the target is the right one. Peripherally there is glucose-dependent insulin secretion, glucagon suppression and delayed gastric emptying, but the gastric component largely adapts over months while the central effect persists, which is why the durable effect is appetite rather than fullness.

Where I think it is weakest: the follow-up is short relative to how long people actually take these drugs, so durability is an assumption here rather than a finding.

What I am after is which effects tachyphylax and which persist, because the answer explains why tolerability improves while the appetite effect keeps working. If the honest answer is that nobody knows, that is a useful answer and I would rather have it.

Note on sourcing:
Figures above are from the primary publication rather than the press summary. If a number here disagrees with one you have, post yours and we will work out which of us is reading a secondary source.
15 10FitDadDave, RunnerRach, TrialNerd_Beth and 12 others
Reply Quote Save Share Report
Dr.PainCLE
Senior Member
1,234
6,234
Mar 2024
Cleveland, OH
Apr 16, 2025 at 2:49 AM#2
maria_elpaso said:
The mechanism is more central than most summaries suggest.

Pharmacist here. I want to add the drug interaction perspective on the pharmacology.

Key points from a pharmacokinetic standpoint:

  • GLP-1 agonists delay gastric emptying, which can affect Tmax of co-administered oral medications
  • Monitor patients on warfarin (INR), levothyroxine (TSH), and oral contraceptives during dose titration
  • The albumin-binding mechanism of semaglutide (C-18 fatty acid linker) gives it the ~168-hour half-life that enables weekly dosing
  • Steady state is reached at approximately 4-5 weeks after dose initiation or adjustment

Re: the pharmacology specifically — the pharmacology here is well-characterized and the clinical implications are straightforward.

14 9tane_welly, Dr.PathRoch, mona_PHX and 11 others
Reply Quote Save Share Report
PurityPaulOR
Senior Member
1,890
7,890
Mar 2024
Oregon
Apr 16, 2025 at 3:05 AM#3
maria_elpaso said:
The mechanism is more central than most summaries suggest.

I read this differently from maria_elpaso, on substance rather than tone. The pharmacokinetics explain nearly every practical question asked here. Albumin binding above 99% slows clearance enough to make weekly dosing possible; a terminal half-life near a week means four to five weeks to steady state and therefore a four-week titration interval; subcutaneous bioavailability around 89% means injection site barely matters. Those three facts answer most timing questions before they are asked.

13 8Admin, Dr.Martinez, mike_mod and 10 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
Dr.NephBHM_UK
Member
456
2,123
Jun 2024
Birmingham, UK
Apr 16, 2025 at 3:21 AM#4
PurityPaulOR said:
The pharmacokinetics explain nearly every practical question asked here.

Receptor pharmacology relevant to the pharmacology: semaglutide is a GLP-1R agonist with a C-18 fatty acid chain that enables albumin binding (>99%), creating a depot effect with a ~168-hour half-life enabling weekly dosing[1].

Tirzepatide is a dual GIP/GLP-1R agonist with higher GIP affinity (5:1 GIP:GLP-1 potency ratio). The GIP component may enhance beta-cell function and adipocyte lipid metabolism beyond what GLP-1 alone achieves.

For the pharmacology, the pharmacology explains the clinical differences between these agents.

References:
[1] Lau J, et al. J Med Chem. 2015;58(18):7370-7380.
Last edited: Apr 16, 2025 at 9:21 AM
12 7SurmountFan_IN, PeptideChemSF, A1cHero_PHX and 9 others
Reply Quote Save Share Report
pat_auckland
Member
345
1,567
Jun 2024
Auckland, NZ
Apr 16, 2025 at 4:45 AM#5
Dr.PainCLE said:
I want to add the drug interaction perspective on the pharmacology.

Mine went the same way, slower.

11 6dan_philly, MeganSA_TX, LarryQC_SD and 8 others
Reply Quote Save Share Report

Similar Threads

BPC-157 oral vs injectable — bioavailability review and evidence15 replies
TB-500 for tissue repair — mechanism and clinical evidence4 replies
Selank and Semax — anxiolytic peptides overview2 replies
CJC-1295/Ipamorelin combination — GH secretagogue discussion23 replies
BPC-157 + GLP-1 stacking for gut healing — N=1 experience17 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register